Aspira Womens Health has a quick ratio of 0.99. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Aspira Womens Health's Quick Ratio or its related term are showing as below:
AWH'
s Quick Ratio Range Over the Past 10 Years
Min: 0.99 Med: 3.23 Max: 5.75
Current: 0.99
During the past 13 years, Aspira Womens Health's highest Quick Ratio was 5.75. The lowest was 0.99. And the median was 3.23.
AWH's Quick Ratio is ranked worse than 77.97% of 236
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.91
vs AWH: 0.99
Aspira Womens Health Quick Ratio Historical Data
The historical data trend for Aspira Womens Health's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's Quick Ratio
For the Diagnostics & Research subindustry, Aspira Womens Health's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's Quick Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Quick Ratio falls into.
Aspira Womens Health Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aspira Womens Health's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (NAS:AWH) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aspira Womens Health Quick Ratio Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (Aspira Womens Health) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AWH has been successfully added to your 